Sign in Register

Drug class

Immunosuppressants - mTOR Inhibitors

Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway. Read more about Immunosuppressants - mTOR Inhibitors

37 drugs in this class 29 manufacturers

Related classes & indications

Alkylating AgentsOncology & immunomodulators · 192 prescription drugs Antirheumatic Agents (DMARDS, non-Biologic)Oncology & immunomodulators · 179 prescription drugs

Showing 10–18 of 37 drugs

Sort

TORPENZ (everolimus)

ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6

Upsher-Smith Laboratories

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

Major Pharamceuticals

EVEROLIMUS

ANTINEOPLASTIC - MTOR KINASE INHIBITORS · METASTATIC RENAL CELL CARCINOMA ·+6

NORTHSTAR RX LL

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

NORTHSTAR RX LL

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

CAMBER PHARMACE

EVEROLIMUS

ANTINEOPLASTIC - MTOR KINASE INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

PAR HEALTH USA,

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

AVPAK

EVEROLIMUS

ANTINEOPLASTIC - MTOR KINASE INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

BRECKENRIDGE

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1

APOTEX CORP

Filter & compare in the drug finder → Opens the drug finder with Immunosuppressants - mTOR Inhibitors preselected. Add indication or manufacturer filters there.

About Immunosuppressants - mTOR Inhibitors.

Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway.

Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle.

Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients.

They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors.

nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
nih.gov
Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
nih.gov
They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors